- Home
- Publications
- Publication Search
- Publication Details
Title
Daclatasvir
Authors
Keywords
-
Journal
ANNALS OF PHARMACOTHERAPY
Volume 50, Issue 1, Pages 39-46
Publisher
SAGE Publications
Online
2015-10-21
DOI
10.1177/1060028015610342
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment
- (2015) Tushar Garimella et al. ANTIVIRAL THERAPY
- Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
- (2015) Gregory J. Dore et al. GASTROENTEROLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C
- (2015) Yoshihide Ueda et al. HEPATOLOGY RESEARCH
- Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders
- (2015) Donald Jensen et al. JOURNAL OF HEPATOLOGY
- A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection
- (2015) Tarek Hassanein et al. JOURNAL OF HEPATOLOGY
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) David L. Wyles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides
- (2015) Vineela Chukkapalli et al. VIROLOGY
- Sofosbuvir
- (2014) Lucia Rose et al. ANNALS OF PHARMACOTHERAPY
- Ledipasvir-Sofosbuvir
- (2014) Michael A. Smith et al. ANNALS OF PHARMACOTHERAPY
- Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity
- (2014) Chunfu Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection
- (2014) Fumitaka Suzuki et al. ANTIVIRAL THERAPY
- Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1
- (2014) Namiki Izumi et al. ANTIVIRAL THERAPY
- The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus
- (2014) Timothy Eley et al. CLINICAL DRUG INVESTIGATION
- Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
- (2014) Adriano M. Pellicelli et al. DIGESTIVE AND LIVER DISEASE
- Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
- (2014) Christophe Hézode et al. GUT
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
- (2014) Hiromitsu Kumada et al. HEPATOLOGY
- Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
- (2014) Makonen Belema et al. JOURNAL OF MEDICINAL CHEMISTRY
- Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition
- (2014) James H. Nettles et al. JOURNAL OF MEDICINAL CHEMISTRY
- Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1
- (2014) K. Kosaka et al. JOURNAL OF VIRAL HEPATITIS
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
- (2014) Michael Manns et al. LANCET
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone
- (2014) Tushar Garimella et al. Journal of the International AIDS Society
- Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement
- (2013) Virginia A. Moyer ANNALS OF INTERNAL MEDICINE
- Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
- (2013) Marc Bifano et al. ANTIVIRAL THERAPY
- Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
- (2013) Marc Bifano et al. ANTIVIRAL THERAPY
- Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
- (2013) Gregory T. Everson et al. GASTROENTEROLOGY
- 794 THE EFFECT OF COADMINISTRATION OF THE PROTON-PUMP INHIBITOR OMEPRAZOLE ON THE PHARMACOKINETICS OF DACLATASVIR IN HEALTHY SUBJECTS
- (2013) M. Bifano et al. JOURNAL OF HEPATOLOGY
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
- (2013) J. Guedj et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
- (2012) Yoshiyuki Suzuki et al. JOURNAL OF HEPATOLOGY
- Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
- (2012) Stanislas Pol et al. LANCET INFECTIOUS DISEASES
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
- (2011) Richard E. Nettles et al. HEPATOLOGY
- Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
- (2011) Robert A. Fridell et al. HEPATOLOGY
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
- (2011) Marc G. Ghany et al. HEPATOLOGY
- Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
- (2011) Kazuaki Chayama et al. HEPATOLOGY
- The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein
- (2011) Choongho Lee et al. VIROLOGY
- Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
- (2010) R. A. Fridell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started